-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, R916w9/mtJbSgP2yIhn+Aw6UWGC2kXzVcbH4SJdPJVXFh9R0qMF0yo1FQNxDmokx AmjqCDyKIasDzcCOug/CTA== 0001257957-08-000030.txt : 20080521 0001257957-08-000030.hdr.sgml : 20080521 20080521215729 ACCESSION NUMBER: 0001257957-08-000030 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20080520 FILED AS OF DATE: 20080521 DATE AS OF CHANGE: 20080521 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AVI BIOPHARMA INC CENTRAL INDEX KEY: 0000873303 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 930797222 STATE OF INCORPORATION: OR FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE SW COLUMBIA STREET 2: STE 1105 CITY: PORTLAND STATE: OR ZIP: 97258 BUSINESS PHONE: 5032270554 MAIL ADDRESS: STREET 1: ONE SW COLUMBIA STREET 2: SUITE 1105 CITY: PORTLAND STATE: OR ZIP: 97258 FORMER COMPANY: FORMER CONFORMED NAME: ANTIVIRALS INC DATE OF NAME CHANGE: 19970123 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Price Ben Gil CENTRAL INDEX KEY: 0001417915 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-14895 FILM NUMBER: 08853235 BUSINESS ADDRESS: BUSINESS PHONE: 240-426-4695 MAIL ADDRESS: STREET 1: 801 INSPIRATION LANE CITY: GAITHERSBURG STATE: MD ZIP: 20878 4 1 edgardoc.xml PRIMARY DOCUMENT X0202 4 2008-05-20 0 0000873303 AVI BIOPHARMA INC AVII 0001417915 Price Ben Gil ONE SW COLUMBIA, SUITE 1105 PORTLAND OR 97258 1 0 0 0 Common Stock 25000 D Non-Qualified Stock Option (right to buy) 1.55 2008-05-20 4 A 0 20000 A 2008-06-20 2018-05-20 Common Stock 20000 20000 D Non-Qualified Stock Option (right to buy) 2.83 2007-10-29 2017-10-29 Common Stock 33000 33000 D Option Grant vests monthly until all shares are vested one year from date of grant. Price not required on initial report of stock option granted. Vesting: 25% of the shares vest each year from the date of grant with all shares vesting in four years. By: Mark M Webber, Attorney-in-fact For: Ben Gill Price MD 2008-05-21 -----END PRIVACY-ENHANCED MESSAGE-----